Zion Pharma is a technology company.
Zion Pharma has raised $69.0M across 3 funding rounds.
Zion Pharma has raised $69.0M in total across 3 funding rounds.
Zion Pharma has raised $69.0M in total across 3 funding rounds.
Zion Pharma's investors include Qiming Venture Partners.
Zion Pharma is a biotechnology company specializing in the development of small-molecule drugs primarily targeting oncology, with a focus on tumor treatment. Its lead product candidates include selective tyrosine kinase inhibitors designed to treat HER2-positive breast cancer and other solid tumors, with an emphasis on addressing brain metastases through blood-brain barrier penetration. Zion Pharma serves cancer patients and healthcare providers by developing therapies that aim to improve outcomes where current options are limited. The company has demonstrated strong growth momentum, highlighted by its partnership with Roche, which acquired worldwide rights to develop and commercialize its lead drug candidate, ZN-A-1041[1][2][3].
Founded in 2018 and headquartered in Shanghai, China, Zion Pharma was co-founded by Dr. Zack Cheng, who also serves as chairman and CEO. The company emerged from a vision to develop innovative oncology therapies that address unmet medical needs, particularly in difficult-to-treat cancers involving brain metastases. Early traction was marked by rapid progression from company formation to first-in-human clinical trials within five years, culminating in a significant licensing deal with Roche that underscores the company's successful drug development and strategic positioning[3][4].
Zion Pharma rides the growing trend of precision oncology and targeted therapies, particularly in the realm of small-molecule drugs that can cross the blood-brain barrier—an area of increasing focus due to the high incidence of brain metastases in cancer patients. The timing is favorable given advances in molecular biology, drug design, and regulatory support for innovative cancer treatments. By addressing a critical gap in treating brain metastases, Zion Pharma influences the broader biotech ecosystem by pushing forward the frontier of targeted cancer therapies and fostering collaboration between emerging biotech firms and global pharmaceutical leaders like Roche[1][3].
Looking ahead, Zion Pharma is poised to advance its clinical pipeline and potentially bring its lead therapies to market through Roche’s global infrastructure. Trends shaping its journey include increasing demand for targeted cancer treatments with CNS penetration and growing investment in oncology innovation. As its therapies progress through clinical development and regulatory milestones, Zion Pharma’s influence is likely to expand, potentially setting new standards for treating metastatic cancers involving the brain. Its trajectory from a startup to a partner of a major pharma within five years exemplifies its potential to impact patient care and the biotech industry significantly[3][4].
Zion Pharma has raised $69.0M across 3 funding rounds. Most recently, it raised $37.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $37.0M Series B | Qiming Venture Partners | |
| Aug 1, 2020 | $20.0M Series A | Qiming Venture Partners | |
| Dec 1, 2018 | $12.0M Series A | Qiming Venture Partners |